In a subset population with T2DM and CKD, GLP-1 RAs were not linked with a lower risk of the composite cardiovascular endpoint (three-point composite MACE), compared to placebo (odds ratio: 0.80; 95% CI: 0.59–1.07; P = 0.13). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.